Artrya AI medical technology to test disease risk
PERTH: A Perth company using artificial intelligence technology to identify people at risk of heart disease has won $1 million in Federal funding.
John Barrington-led Artrya will use a chunk of the money to employ PhD students from the University of Western Australia. The computer science and medicine students will help ready the technology that can identify in minutes the high-risk plaques and restricted blood flows that kill thousands of Australians each year.
The extra funds come months after the company reaped $2.8m from sophisticated investors in an over-subscribed capital raising this year.
“The funding will quicken Artrya’s push towards commercialisation as it refines its product, clinically validates the solution, attracts further equity and builds strong foundations for larger trials and regulatory approval,” Mr Barrington said. Artrya uses AI algorithms to identify the plaques that are prone to rupturing and to pinpoint areas of the heart experiencing ischemia. Its developers believe it is more effective than traditional tests, such as CT coronary angiography scans.
Artrya co-founder and chief executive John Konstantopoulos said the company’s technology generated a diagnosis in under two minutes.
“By combining latest advances in AI, image processing, data analysis and CAD research, everything is cheaper, faster and more accurate,” he said. “Early feedback from clinicians on Artrya’s technology is encouraging.”
Artrya’s $1m came through the third round of the Federal Government’s BioMedTech Horizons Program.







